The company highlighted a series of strategic moves during the year, including the acquisition of WOKADINE, marking its entry into the Rs. 648 Cr Povidone Iodine market
In collaboration with the Soham Foundation, the initiative focused on perimenopause, menopause, and hormone replacement therapy awareness at BESCOM’s Bengaluru headquarters.
The initiative aims to encourage women and parents to seek timely medical guidance on cervical cancer prevention and HPV awareness
Funds to support product expansion, quick commerce growth, and manufacturing scale-up for holistic period care solutions
On the generics and biosimilars front, the combined business is expected to benefit from Sun’s portfolio of more than 550 approved ANDAs across multiple dosage forms
Acquisition to expand the company's women’s health and biosimilars footprint, positioning it among top 25 drugmakers globally
Final approval for progesterone vaginal inserts expands Glenmark’s women’s healthcare portfolio in the US, targeting a market of over $59 million
This approval marks a significant milestone in women’s health, introducing Bayer’s first hormone-free treatment for menopause-related symptoms
Donation drive in São Paulo aims to support 250 young women’s health and environmental responsibility
Sleep disturbances are among the most frequent and disruptive symptoms associated with menopause which can impact women’s health and quality of life
Subscribe To Our Newsletter & Stay Updated
